Hint Inc. Raises $10.0M Seed Funding

Dolfin

Dolfin Partners is a specialty finance company providing long-term lease financing for capital expenditures associated with commercial space. The Dolfin Lease is a private, bilateral financing instrument priced on the tenant's credit, not the real estate. Fixed rate. Fully amortizing. Unsecured. Structured from 10 to 20 years to match the useful life of the asset. No collateral pledge. No balloon payment. No refinancing risk. For corporate tenants: Your build-out is a long-term asset. Your financing should be too. If your company is investment-grade or near-IG, you likely qualify. Dolfin finances 100% of your tenant improvements, equipment, and soft costs during construction — converting your capital expenditure into a single, fixed-rate lease at completion. No upfront equity required. No revolver draw. No asset pledge. For improvements already funded, Dolfin reimburses 100% of your sunk costs at close, freeing that capital to be redeployed into your core business. For landlords: Replace your TI equity. Dolfin holds the lease obligation — you hold the space. Non-recourse, no property liens or senior lender approval. New York, NY

Autoimmunity BioSolutions

Autoimmunity BioSolutions (ABS) is pioneering a personalized, genetically guided immuno-corrective therapy designed to normalize or "correct" elevated levels of soluble IL7 receptor (sIL7R), a fundamental driver of poor therapeutic response in autoimmune disease. This therapy targets a genetically defined subpopulation of autoimmune disease patients marked by a highly prevalent genetic variant (SNP) associated with greater severity of disease, increased progression of disease, and poor response to current treatments. This immuno-corrective approach of targeting sIL7R in a genetic population is highly differentiated from current standards of care that rely on immunosuppressive mechanisms and has broad potential to treat numerous autoimmune diseases.

Secludy AI

Privacy-guaranteed synthetic data generation for training AI models

BranchLab

BranchLab is the AI platform for biopharma commercialization. Biopharma companies and their marketing agencies in-house BranchLab’s platform to model high-value patient and provider populations, activate omnichannel, and measure real-world outcomes without using personal health data. The BranchLab platform is designed to streamline how therapies are brought to market in the AI era

WiseCost, Inc.

WiseCost helps government contractors stay DCAA compliant with less effort and greater accuracy. From automated time tracking and job costing to indirect rate calculations and audit-ready reports, we provide everything small and mid-sized GovCons need to run a fully compliant accounting system. Built for teams that rely on QuickBooks Online, WiseCost eliminates spreadsheets, manual adjustments, and audit risks — giving contractors a powerful, intuitive platform to manage compliance and profitability in one place.